Services / Advising and Medical Writing

Advising and Medical Writing

Investigación

Medical writing includes the preparation and delivery of a wide variety of documents and services. In this sense, having a strong, experienced strategic partner, with deep and broad knowledge covering several therapeutic areas ensures an adequate knowledge management.

Evidenze has a strong team of professionals with medical-related background, biologists and epidemiologists with over 6 years of experience, under permanent training and updating on different therapeutic areas.

Among the services offered by our medical writing team are:

  • Scientific and technical consulting
  • Technical consultation to Competent Authorities
  • Development of study proposals (from Phase I to Phase IV and observational)
  • Study Protocols
  • Design of Case Report Forms
  • Clinical Study Reports / Clinical Trial Reports
  • Manuscripts
  • Conference Materiales (Abstracts, poster presentation and slide sets)
  • Meeting and Conference Reports
  • Summary of Product Characteristics
  • Literature Reviews
  • Scientific Documents (medical marketing reviews, educational material, etc)

The main areas of work are Oncology (40%), Cardiovascular and Diabetes (25%), Neurology (20%), and Infectious diseases (10%).

The main activity of the department is focused on the development of protocols. 35% of them are clinical trials related (Phase I to Phase IV) and the remaining corresponds to observational studies.

Regarding the conference submission of scientific documents, Evidenze produces an average of 90 abstracts per year, 80% of them are submitted to international conferences, covering the major therapeutic areas. Currently, our acceptance rate is over 90%.

In reference to original manuscripts, the key is to have a CRO with extensive experience in this area, coupled with the internal resources able to conduct the research and also to implement its related results and recommendations. Our company has an overall publication rate of 73% (55.7% in its first submission).

90% of our manuscripts were for international publications, according to the following breakdown:

  • 40% of the manuscripts reported the results of clinical trials (75% of which were sponsored by independent researchers or cooperative groups, and 25% sponsored by pharmaceutical companies)
  • 60% of the manuscripts reported the results of non-interventional studies (20% sponsored by independent researchers or cooperative groups; 80% were pharma-sponsored)